Revenue: As of FY2025 Q4, the actual value is USD 901 K, missing the estimate of USD 1.4 M.EPS: As of FY2025 Q4, the actual value is USD -0.97, missing the estimate of USD -0.66.<h4>Consolidated Balance Sheet Highlights (In thousands)</h4><ul><li>Total assets for Arcadia Biosciences, Inc. were $6,546 as of December 31, 2025, a decrease from $13,517 as of December 31, 2024.</li><li>Total current assets decreased to $6,356 as of December 31, 2025, from $9,242 as of December 31, 2024.</li><li>Cash and cash equivalents significantly decreased to $259 as of December 31, 2025, from $4,242 as of December 31, 2024.</li><li>Total liabilities decreased to $2,406 as of December 31, 2025, from $7,294 as of December 31, 2024.</li><li>Total stockholders’ equity was $4,140 as of December 31, 2025, down from $6,223 as of December 31, 2024.</li><li>The accumulated deficit increased to -$281,217 as of December 31, 2025, from -$278,878 as of December 31, 2024.</li></ul><h4>Consolidated Statements of Operations Highlights (In thousands)</h4><ul><li>Total revenues for the year ended December 31, 2025, were $4,858, a slight decrease from $5,045 for the year ended December 31, 2024.</li><li>Product revenue was $4,858 in 2025, compared to $5,012 in 2024.</li><li>Cost of revenues increased to $3,098 in 2025 from $2,963 in 2024.</li><li>Gross margin was $1,760 in 2025, down from $2,082 in 2024.</li><li>Research and development expenses decreased to $9 in 2025 from $53 in 2024.</li><li>Selling, general and administrative expenses decreased to $7,001 in 2025 from $9,641 in 2024.</li><li>Total operating expenses were $7,358 in 2025, a decrease from $8,693 in 2024.</li><li>The operating loss was -$2,500 in 2025, an improvement from an operating loss of -$3,648 in 2024.</li><li>Operating margin was -51.46% in 2025, an improvement from -72.31% in 2024.</li><li>Net loss from continuing operations was -$2,339 in 2025, an improvement from -$4,317 in 2024.</li><li>The net loss attributable to common stockholders was -$2,339 in 2025, significantly better than -$7,038 in 2024.</li><li>Comprehensive loss for 2025 was -$2,339, compared to -$7,139 in 2024.</li></ul><h4>Consolidated Statements of Cash Flows Highlights (In thousands)</h4><ul><li>Net cash used in operating activities decreased to -$4,739 for the year ended December 31, 2025, from -$9,627 for the year ended December 31, 2024.</li><li>Net cash provided by investing activities was $750 in 2025, a decrease from $7,342 in 2024.</li><li>Net cash provided by financing activities was $6 in 2025, slightly down from $9 in 2024.</li><li>Free cash flow was -$4,739 in 2025, compared to -$9,643 in 2024.</li><li>The net decrease in cash and cash equivalents was -$3,983 in 2025, compared to -$2,276 in 2024.</li></ul>

Arcadia Biosciences | 8-K: FY2025 Q4 Revenue Misses Estimate at USD 901 K